Jun 20, 2024 | Publications
PUBLICATIONS > Évaluation du taux de récidive chez les patientes canadiennes atteintes d’un cancer du sein HR+/HER2- de stade II/III à partir de données de santé de vie réelle 20 juin 2024 Évaluation du taux de récidive chez les patientes canadiennes... 
Jun 19, 2024 | Publications
PUBLICATIONS > Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada 19 June 2024 Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada Qi Guan 1,2, Suriya J. Aktar 1,2, Reka E. Pataky 2,3,4, Mariet... 
May 15, 2024 | News
NEWS > PRESS RELEASE – Exactis Innovation and PeriPharm Forge Strategic Collaboration to Advance Real-World Evidence Studies 15 May 2024 Exactis Innovation and PeriPharm Forge Strategic Collaboration to Advance Real-World Evidence Studies Exactis Innovation... 
Apr 4, 2024 | News
NEWS > A Word from the CEO 04 April 2024 A Word from the CEO 10,000 Patients Enrolled in Our Pan-Canadian Oncology Databank I am thrilled to share a significant milestone in the journey of Exactis Innovation. This month, we marked the enrollment of the... 
Mar 25, 2024 | News
NEWS > From the lab to the front lines of RWE research 26 March 2024 From the lab to the front lines of RWE research MEET ADRIANA ORIMOTO, PMT COORDINATOR AT THE CENTRE HOSPITALIER DE L’UNIVERSITÉ DE MONTREAL (CHUM) Adriana Orimoto discovered her passion for... Dec 20, 2023 | News
NEWS > A Word from the CEO 20 December 2023 A Word from the CEO Closing the Gap: Canada’s Urgent Need for Innovation in Life Sciences through Connected Health Data As we end 2023, Canada’s life science ecosystem finds itself at a critical juncture. Having... 
Dec 19, 2023 | Publications
PUBLICATIONS > A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy 19 December 2023 A Phase II Exploratory Study to Identify Biomarkers... 
Dec 13, 2023 | Publications
PUBLICATIONS > Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada 13 December 2023 Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of...Dec 11, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > STÉPHANIE MICHAUD BOARD OF DIRECTORS STÉPHANIE MICHAUD PRESIDENT AND CEO, BIOCANRX Stéphanie Michaud brings over 20 years of public, government and private sector experience in research, science, technology and...Dec 11, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > ANNE WOODS BOARD OF DIRECTORS ANNE WOODS MANAGING DIRECTOR, LIFE SCIENCES & HEALTHCARE, RBCx Anne is the Managing Director of Life Sciences & Healthcare at RBCx where she brings over 25 years of...Dec 11, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > SAMIR COURDY BOARD OF DIRECTORS SAMIR COURDY SENIOR VICE PRESIDENT, CHIEF INFORMATICS OFFICER AT CITY OF HOPE COMPREHENSIVE CANCER CENTER Samir Courdy is the SVP, Chief Informatics Officer for City of Hope...Dec 11, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > JEAN-FRANCOIS BALADI BOARD OF DIRECTORS JEAN-FRANCOIS BALADI MARKET ACCESS EXPERIENCED PROFESSIONAL Jean-Francois Baladi brings more than 30 years of experience in industry and research in the fields of health...Dec 11, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > AARON LEIBTAG BOARD OF DIRECTORS AARON LEIBTAG CEO & CO-FOUNDER OF PENTAVERE Aaron Leibtag is the cofounder and CEO of Pentavere, a globally recognized and award-winning AI digital health company that has...Dec 7, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > AARON CHAO OPERATIONS TEAM AARON CHAO DATA AND ANALYTICS ENGINEER Aaron obtained his B.Math at the University of Waterloo majoring in Data Science. Over the past 5 years, he has played a critical role in building and... 
Dec 5, 2023 | Publications
PUBLICATIONS > San Antonio Breast Cancer Symposium, December 2023 5-9 December 2023 San Antonio Breast Cancer Symposium Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative... 
Nov 12, 2023 | Publications
PUBLICATIONS > Canadian Cancer Research Conference, November 2023 12-14 November 2023 Canadian Cancer Research Conference The Prognostic Value of Circulating Tumor DNA in Triple Negative Breast Cancer Patients with Incomplete Response to Neoadjuvant Chemotherapy...Oct 31, 2023 | Team
ABOUT US > OUR team > operations TEAM > Winston Wu OPERATIONS TEAM Dr. Bill Evans, MD, FRCPC Consultant for Exactis Dr. Bill Evans is a medical oncologist and former healthcare administrator who directed cancer centres in Ottawa and Hamilton and served as the...Oct 31, 2023 | Team
ABOUT US > OUR team > operations TEAM > Winston Wu MANAGEMENT TEAM Winston Wu Chief Technology Officer Winston Wu joins Exactis with 20 years of technology and business experience in both consulting and industry. Winston consulted across many domains and...Oct 31, 2023 | Team
ABOUT US > OUR TEAM > MANAGEMENT TEAM > Diana Salazar, MBA, MSC MANAGEMENT TEAM DIANA SALAZAR, MBA, MSC Director, Network Engagement Diana completed a bachelor’s degree in Biology (Major: genetics) at the University of Antioquia (Medellin, Colombia), a Master...Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > MYRIAM COSSETTE-VOYER LLB, MBMD BOARD OF DIRECTORS MYRIAM COSSETTE-VOYER, LLB, MBMD CORPORATE SECRETARY Ms Cossette-Voyer was admitted to the Quebec Bar in 2012 after completing a Baccalaureate in Law and a...Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > YVONNE BOMBARD, PHD BOARD OF DIRECTORS YVONNE BOMBARD, PHD ASSOCIATE PROFESSOR AT THE INSTITUTE OF HEALTH POLICY, MANAGEMENT AND EVALUATION AT THE UNIVERSITY OF TORONTO Dr. Yvonne Bombard is a genomics health...Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > DR. ALAN SPATZ BOARD OF DIRECTORS DR. ALAN SPATZ DEPARTMENT OF PATHOLOGY – JGH, PROFESSOR OF PATHOLOGY AND ONCOLOGY – MCGILL UNIVERSITY, PROGRAM DIRECTOR – MCGILL INTEGRATED CANCER RESEARCH...Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > MA’N H. ZAWATI BOARD OF DIRECTORS MA’N H. ZAWATI, LLB, LLM, PHD (DCL) ASSISTANT PROFESSOR AT MCGILL UNIVERSITY’S FACULTY OF MEDICINE AND EXECUTIVE DIRECTOR OF THE CENTRE OF GENOMICS AND POLICY IN THE...Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > DR. ALLAN MANDELZYS BOARD OF DIRECTORS DR. ALLAN MANDELZYS, PHD, MBA, LIFE SCIENCES ADVISOR & MENTOR AT CEIM (CENTRE D’ENTERPRISE ET D’INNOVATION DE MONTRÉAL) Dr. Allan Mandelzys is currently a member of...Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > BARRY D. STEIN BOARD OF DIRECTORS BARRY D. STEIN, BCOM, BCL, LLB CEO OF COLORECTAL CANCER CANADA Mr. Barry D. Stein graduated from McGill University and has been a member of the Barreau du Quebec since 1981. An...Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > DR. KELVIN KAR-WING CHAN BOARD OF DIRECTORS DR. KELVIN KAR-WING CHAN, MD, FRCPC, M.SC., PHD MEDICAL ONCOLOGIST, ASSOCIATE SCIENTIST AT THE ODETTE CANCER CENTRE OF THE SUNNYBROOK HEALTH SCIENCES CENTRE Dr....Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > RAPHAEL (RAFI) HOFSTEIN BOARD OF DIRECTORS RAPHAEL (RAFI) HOFSTEIN, PHD LIFE-SCIENCE EXECUTIVE, PAST CEO OF TIAP (FORMERLY MARS INNOVATION) Dr. Raphael (Rafi) Hofstein is Past-President and CEO of TIAP having...Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > DR. SUSAN W. PITMAN LOWENTHAL BOARD OF DIRECTORS DR. SUSAN W. PITMAN LOWENTHAL PAST SENIOR DIRECTOR AT...Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > DR. ANNE-MARIE MES-MASSON BOARD OF DIRECTORS DR. ANNE-MARIE MES-MASSON, DIRECTOR RÉSEAU DE RECHERCHE SUR LE CANCER, CANCER THEME LEADER AT THE CRCHUM Dr. Anne-Marie Mes-Masson is the Scientific Director of the...Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > DR. GERALD BATIST BOARD OF DIRECTORS DR. GERALD BATIST EXACTIS INNOVATION CO-FOUNDER AND SCIENTIFIC DIRECTOR, DIRECTOR SEGAL CANCER CENTER, SIR MORTIMER B. DAVIS-JEWISH GENERAL HOSPITAL Dr. Gerald Batist is a...Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > DR. TERRY SULLIVAN BOARD OF DIRECTORS DR. TERRY SULLIVAN, PAST CEO OF CANCER CARE ONTARIO Dr. Terry Sullivan is Professor in the Institute of Health Policy, Management and Evaluation (Faculty of Medicine), the...Oct 18, 2023 | Governance
ABOUT US > OUR GOVERNANCE > BOARD OF DIRECTORS > MAHA KATABI, PHD, CFA BOARD OF DIRECTORS MAHA KATABI, PHD, CFA CHAIR OF THE BOARD OF EXACTIS INNOVATION, PARTNER SOFINNOVA Dr. Maha Katabi joined Sofinnova as a Partner in 2019 and is a member of the Board of...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > SAMANTHA PARKER OPERATIONS TEAM SAMANTHA PARKER ADMINISTRATIVE ASSISTANT AND CONTENT COORDINATOR Samantha joined Exactis in July 2022. She is responsible for coordinating administrative activities, as well as assisting...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > ÉMILIE FARRAN OPERATIONS TEAM ÉMILIE FARRAN WELLNESS AND HUMAN RESOURCES MANAGER Emilie Farran joined Exactis Innovation’s team in May 2017 as an administrative assistant and was promoted in April 2022 to Wellness and...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > PHIL MOORE OPERATIONS TEAM PHIL MOORE IT ANALYST Phil Moore worked for Apple for seven years before joining Exactis in 2017, and brings over 16 years of experience in IT support. He is responsible for handling...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > DR. KAHINA RACHEDI, MD OPERATIONS TEAM DR. KAHINA RACHEDI, MD MEDICAL INFORMATION SPECIALIST Dr. Kahina Rachedi holds a medical degree with a specialization in obstetrics, gynecology, and breast cancer surgery from the...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > CYRIELLE BEAUBOIS, MSC OPERATIONS TEAM CYRIELLE BEAUBOIS, MSC SENIOR DATA MANAGER Cyrielle Beaubois obtained her B.SC at Bordeaux 2 University (France) and her M.Sc in Public Health and Epidemiology at the Institute of...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > VINCENT NORMANDEAU-BABIN, MSC OPERATIONS TEAM VINCENT NORMANDEAU-BABIN, MSC IT PROJECT MANAGER Vincent Normandeau-Babin obtained a Bachelor’s degree in Bioinformatics from the Université de Montréal. He also holds a MSc...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > ROSA CHRISTODOULOPOULOS, PHD OPERATIONS TEAM ROSA CHRISTODOULOPOULOS, PHD PMT SITE MANAGER Dr. Garyfallia (Rosa) Christodoulopoulos is a graduate of McGill University, where she obtained a PhD in the department of...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > LOUBABA CHERKAOUI, MSC OPERATIONS TEAM LOUBABA CHERKAOUI, MSC QUALITY CONSULTANT Loubaba Cherkaoui is a clinical expert with profound knowledge and extensive experience in Quality Assurance, GCPs and related regulations...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > GALINA POGOSSOVA OPERATIONS TEAM GALINA POGOSSOVA CLINICAL TRIAL ASSISTANT Galina Pogossova obtained a Bachelor’s degree from McGill University. Over the past 10 years, in her capacity as a research assistant, Galina...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > HASMITA PATEL OPERATIONS TEAM HASMITA PATEL SENIOR CLINICAL TRIAL ASSISTANT Hasmita Patel has over 15 years experience in the CRO industry. Over the years she has gained valuable expertise in the recruitment and...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > MARIA VERSHININ, MSC OPERATIONS TEAM MARIA VERSHININ, MSC CLINICAL RESEARCH ASSOCIATE Maria Vershinin joined Exactis in June 2022 as a clinical research associate. She obtained her MSc in Biopharmaceutical Sciences at...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > SYEDA IRINE ISLAM, MSC OPERATIONS TEAM SYEDA IRINE ISLAM, MSC CLINICAL RESEARCH ASSOCIATE Syeda Irine Islam obtained her MSc in Biochemistry at Université de Montréal in 2020. Her most recent experience was at an...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > CLIONA LITTLE OPERATIONS TEAM CLIONA LITTLE PROJECT MANAGER – DATA STRATEGY Cliona Little graduated with a Bachelor’s degree in Electronic Engineering from University College Dublin (Ireland). She began her career as a...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > PASCALE BRISEBOIS OPERATIONS TEAM PASCALE BRISEBOIS PROJECT MANAGER Pascale Brisebois joined the Exactis team in November 2020 as a Clinical Research Associate and was promoted in June 2022 to Project Manager. She...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > YASMINE MADAGH-BISKRI, MSC OPERATIONS TEAM YASMINE MADAGH-BISKRI, MSC SENIOR PROJECT MANAGER Yasmine Madagh-Biskri obtained her MSc in Molecular Chemistry at Pierre and Marie Curie University (France). She has previous...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > OPERATIONS TEAM > DINA DELLA ROCCA, RN, BSC OPERATIONS TEAM DINA DELLA ROCCA, RN, BSC DIRECTOR, CLINICAL & NETWORK OPERATIONS Dina Della Rocca joined Exactis in November 2021 as the Clinical Operations Manager and was promoted in May...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > MANAGEMENT TEAM > MYRIAM COSSETTE-VOYER, LLB, MBMD MANAGEMENT TEAM MYRIAM COSSETTE-VOYER, LLB, MBMD EXTERNAL LEGAL COUNSEL AND CORPORATE SECRETARY Myriam Cossette-Voyer was admitted to the Quebec Bar in 2012 after completing a...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > MANAGEMENT TEAM > DR. BILL EVANS, MD, FRCPC MANAGEMENT TEAM DR. BILL EVANS, MD, FRCPC CONSULTANT FOR EXACTIS Dr. Bill Evans is a medical oncologist and former healthcare administrator who directed cancer centres in Ottawa and Hamilton...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > MANAGEMENT TEAM > MICHEL LEMIEUX, MBA, CPA, CMA MANAGEMENT TEAM MICHEL LEMIEUX, MBA, CPA, CMA MANAGERIAL ACCOUNTANT Michel Lemieux joined Exactis in early 2019 as a managerial accountant. Before joining Exactis Innovation, Michel held...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > MANAGEMENT TEAM > MAUD MARQUES, PHD MANAGEMENT TEAM MAUD MARQUES, PHD DIRECTOR, SCIENTIFIC STRATEGY Dr. Maud Marques holds a PhD degree in Cellular and Molecular Biology from the Université de Sherbrooke (Canada). She completed a 5-year...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > MANAGEMENT TEAM > KAREN GAMBARO, PHD MANAGEMENT TEAM KAREN GAMBARO, PHD DIRECTOR, TRANSLATIONAL OPERATIONS Dr. Karen Gambaro holds a PhD degree in Cellular and Molecular Biology from the University of Nice-Sophia Antipolis (France). She...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > MANAGEMENT TEAM > LESTER POON MANAGEMENT TEAM LESTER POON CHIEF DEVELOPMENT OFFICER As Chief Development Officer, Lester Poon is responsible for promoting Exactis Innovation’s vision and mission, and securing sustainable industry...Oct 18, 2023 | Team, Team
ABOUT US > OUR TEAM > MANAGEMENT TEAM > SUZAN MCNAMARA, PHD MANAGEMENT TEAM SUZAN MCNAMARA, PHD CHIEF OPERATING OFFICER As Chief Operating Officer, Dr. Suzan McNamara is responsible for the operational functions of the organization which includes leadership,...Oct 18, 2023 | Team
ABOUT US > OUR TEAM > MANAGEMENT TEAM > DR. GERRY BATIST, MD MANAGEMENT TEAM DR. GERRY BATIST, MD CHIEF MEDICAL OFFICER Dr. Gerry Batist is a medical oncologist and molecular pharmacologist. He is Director of the McGill Centre for Translational Research in...Oct 18, 2023 | Team, Team
ABOUT US > OUR TEAM > MANAGEMENT TEAM > KOSTAS TRAKAS, PHD MANAGEMENT TEAM KOSTAS TRAKAS, PHD CHIEF EXECUTIVE OFFICER Dr. Kostas Trakas joins Exactis from Noviscend Inc. where he was CEO and co-founder. Noviscend is a healthcare company distributing... 
Jun 20, 2023 | News
NEWS > Gamer, podcaster, clinical trial assistant: the employee behind our new podcast 20 June 2023 Gamer, podcaster, clinical trial assistant: the employee behind our new podcast Galina Pogossovas primary role at Exactis is as a Clinical Trial Assistant (CTA). In... 
May 16, 2023 | Publications
PUBLICATIONS > CADTH Symposium 2023 16 May 2023 CADTH Symposium 2023: PERSONALIZE MY TREATMENT (PMT): A CANADIAN CANCER PATIENT REGISTRY PERSONALIZE MY TREATMENT (PMT): A CANADIAN CANCER PATIENT REGISTRY Maud Marques,1 Karen Gambaro,1Rosa Garyfallia... Mar 29, 2023 | News
NEWS > A Word from the CEO 29 March 2023 A Word from the CEO Over the past couple of years, the U.S. Food and Drug Administration (FDA) has taken a hard-line stance against drug products approved under the accelerated approval pathway, but that have not met their... 
Mar 29, 2023 | News
NEWS > Refusing to take no for an answer 29 March 2023 Refusing to take no for an answer HOW EXACTIS’ COO USED HER OWN BATTLE WITH CANCER TO FIGHT FOR ALL CANCER PATIENTS Dr. Suzan McNamara knew she was too young to die. At 31, she was diagnosed with a rare disease...Mar 29, 2023 | News
NEWS > Moving the needle forward 29 March 2023 Moving the needle forward HOW PMT COORDINATORS ARE HELPING ACCELERATE CANCER RESEARCH In May 2016, Lee-Anne Pickard, a nurse with close to 20 years of experience in cancer research, was sent an article from the... 
Nov 24, 2022 | Publications
PUBLICATIONS > IARC Nov 8-10 conference 2022 22 November 2022 IARC Nov 8-10 conference 2022 Plenary themes under which authors will submit their abstracts:• Registries, research and health policy PERSONALIZE MY TREATMENT (PMT): A CANADIAN CANCER PATIENT REGISTRY.... 
Nov 24, 2022 | Publications
PUBLICATIONS > ESMO Conference: MOLECULAR ANALYSIS FOR PRECISION ONCOLOGY CONGRESS 2022 24 November 2022 ESMO Conference: MOLECULAR ANALYSIS FOR PRECISION ONCOLOGY CONGRESS 2022 Abstract submission deadline: Tuesday, 26 July 2022 Trial in Progress (“TiP”) abstracts...Jan 31, 2022 | News
Sep 3, 2021 | News
We are pleased to have been chosen among the 39 best clinical trial companies in Canada according to the site: https://beststartup.ca/ Here is a summary of the article: This article showcases our top picks for the best Canada based Clinical Trials companies. These...May 3, 2021 | News
Since their initial description in 19481, small DNA fragments travelling in the non-cellular component of internal bodily fluids and excretions have revolutionized numerous fields in public health and preventive medicine2,3,4,5,6. Although its origins have been a... 
May 3, 2021 | Publications
PUBLICATIONS > Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer 3 May 2021 Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer... ![The Next Steps for Precision Oncology in Canada]()
Mar 12, 2021 | News
Exactis Innovation is a pan-Canadian research network that accelerates biomarker-led clinical and translational research in areas of high-unmet medical need. Precision Medicine in Cancer Care The past decade has seen the emergence of precision medicine, a complicated...Sep 29, 2020 | News
Study of lasofoxifene versus fulvestrant in patients with metastatic breast cancer will include seven precision-medicine Exactis Network study locations COLUMBUS, Ohio (September 29, 2020) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company... 
Aug 10, 2020 | Publications
PUBLICATIONS > Evaluating the quantity, quality and size distribution of cell‑free DNA by multiplex droplet digital PCR 10 August 2020 Evaluating the quantity, quality and size distribution of cell‑free DNA by multiplex droplet digital PCR Miguel Alcaide,...Jul 28, 2020 | News
Exactis is pleased to be working with Dr. Jonathan Spicer on a phase I interventional pilot open-label trial, using rhDNase1 as a treatment for COVID-19 positive patients. The objectives are to assess the safety and feasibility of inhaled rhDNase1 in severely ill...Jul 28, 2020 | News
The Exactis-01 trial, a PMT sub-study “Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration Results Using the Oncomine Precision Assay (OPA) in Advanced or Metastatic NSCLC within the Exactis Network” will be open at...Jul 28, 2020 | News
The Exactis-03 trial “A Phase I/II Basket Trial of the Combination of PARP inhibitor and Navitoclax in Women with High Grade Serous Epithelial Ovarian Cancer and Triple Negative Breast Cancer” led by Dr. Helen...Jul 28, 2020 | News
Sermonix Pharmaceuticals’ study “Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation.” The clinical trial is ongoing in the United States, and Exactis is currently performing a feasibility...Jul 28, 2020 | News
Exactis is pleased to be working with Dr. Sébastien Perreault from CHU Ste-Justine on the TRAM-01 study, “ Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway”. This...Jul 28, 2020 | News
Our new manuscript “Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition” is now available in Clinical Proteomics. Our research identified potential protein candidates for a blood-based prognostic signature...Mar 27, 2020 | News
Dear Exactis Network, With the current and ever-evolving situation with COVID-19, we wanted to provide you with an update on our response to date and our commitment moving forward. The health, safety and well-being of participants, and our Network... 
Feb 7, 2020 | Publications
PUBLICATIONS > Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition 7 February 2020 Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition... 
Nov 1, 2019 | Publications
PUBLICATIONS > Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data 1 November 2019 Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data Authors: Bernhard...Jul 29, 2019 | News
Exactis Innovation is pleased to award $1M CDN to catalyze clinical research on innovative precision oncology therapeutics in Canada. This grant will support a multi-centre clinical trial in the Exactis research network comprising eleven premier cancer care...Jul 9, 2019 | News
Read the full article here. 
Jun 26, 2019 | Publications
PUBLICATIONS > Analysis of the genomic landscape in ALK+ NSCLC patients identifies novel aberrations associated with clinical outcomes 26 June 2019 Analysis of the genomic landscape in ALK+ NSCLC patients identifies novel aberrations associated with clinical...Jun 12, 2019 | News
The TRICIA Study, a research project pairing molecular data with artificial intelligence, was awarded funding of $1.6 million this week by the Biopharmaceutical Research Consortium CQDM, the Ministère de l’Économie et de l’Innovation of the Government of Quebec, and... 
Apr 29, 2019 | Publications
PUBLICATIONS > A network approach to developing immuno-oncology combinations in Canada 29 April 2019 A network approach to developing immuno-oncology combinations in Canada Authors: V. Higenell: Exactis InnovationR. Fajzel: Exactis Innovation, Segal Cancer Centre,... 
Apr 22, 2019 | Publications
PUBLICATIONS > Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial 22 April 2019 Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial Authors: Jordi Rodon, Jean-Charles Soria, Raanan Berger,...Mar 27, 2019 | News
We are pleased to share an article on Precision Oncology and the Exactis PMT initiative appearing on www.personalhealthnews.ca, and printed in the April 2019 edition of Maclean’s Magazine, as part of a Mediaplanet special interest “Advancements in Cancer Care...Feb 13, 2019 | News
Exactis Innovation is pleased to formally announce the launch of the Exactis Innovation Investigator-Initiated Trial (IIT) Grant Competition. In alignment with the Exactis Mission to accelerate precision oncology by matching specific molecular or clinical profiles to...Sep 12, 2018 | News
MRM Proteomics Inc. is partnering with Exactis Innovation to develop and validate a clinical proteomic test that will provide clinicians and scientists with the ability to identify immune signatures and tumour mutation profiles to better match patients with the most...Mar 28, 2018 | News
At risk cancer patients across Canada may now be able to have their tumors molecularly profiled using next-generation sequencing (NGS) as part of a national effort to expedite enrollments in clinical trials. Led by Exactis Innovation, a non-profit...Nov 24, 2017 | News
Since November 2015 (when the first PMT participant signed the PMT informed consent form) you have helped us expand PMT throughout Canada and have recruited nearly 1,500 participants to name only a few milestones! The graphic below outlines some of the biggest feats... 
Sep 5, 2017 | Publications
PUBLICATIONS > Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits 5 September 2017 Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded...Dec 13, 2016 | News
Five major Quebec cancer treatment centres are partnering with Montreal-based Exactis Innovation to build a coordinated network to match cancer patients to clinical trials based on the characteristics of their tumour through an innovative digital...Apr 15, 2016 | News
At an announcement made earlier today, Merck confirmed its commitment to research and innovation in oncology by contributing a total of $2 million to the Exactis Innovation ‘Personalize My Treatment’ (PMT) initiative. In addition, the Cancer Research Society (CRS) and...Apr 3, 2014 | News
At the 6th Annual National Conference to Defeat Cancer, organized by Coalition Priorité Cancer, Merck Canada reinforced the company’s continued commitment to the Quebec life sciences research innovation sector by announcing a $2-million grant to the Quebec –...Feb 17, 2014 | News
The Quebec – Clinical Research Organization in Cancer (Q-CROC) was awarded a $9.2 million investment from the Quebec government over four years as part of the Fonds de partenariat pour un Québec innovant et en santé (FPQIS). This public-private partnership was...Jan 31, 2014 | News
The Honourable Greg Rickford, Minister of State (Science and Technology, and Federal Economic Development Initiative for Northern Ontario) announced a $15 million investment for 5 years in a public-private partnership put forward by the Centre of Excellence PreThera... 
Jun 25, 2013 | Publications
PUBLICATIONS > Biopsies: next-generation biospecimens for tailoring therapy 25 June 2013 Biopsies: next-generation biospecimens for tailoring therapy Authors: Mark Basik, Adriana Aguilar-Mahecha, Caroline Rousseau, Zuanel Diaz, Sabine Tejpar, Alan Spatz, Celia M.... 
Jun 7, 2013 | Publications
PUBLICATIONS > Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine 7 June 2013 Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine... 